CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 10:30 a.m. PT (1:30 p.m. ET). Todd Chappell, Chief Operating Officer, and Loic Vincent, Ph.D., Chief Scientific Officer, will also be participating at the conference. A live webcast of the presentation can be accessed on the “Events & Presenta ...

Company Overview - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, creating, testing, and delivering transformative medicines for genetic diseases [3] - Founded in 2015, the company has a pipeline that includes programs from early science to advanced clinical trials [3] - The team consists of experienced drug discoverers, developers, and innovators dedicated to applying advances in genetic medicine [3] Upcoming Events - Co-founder and CEO Neil Kumar, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 7:30 am PT [1] - A live webcast of the investor webinar will be available on the BridgeBio website, with a replay accessible for 30 days post-event [2]

Core Insights - BridgeBio Pharma, Inc. is hosting an investor webinar on January 9, 2026, focusing on infigratinib as a treatment for achondroplasia, a genetic skeletal dysplasia [1][3] - Dr. Janet Legare will present on the pathophysiology of achondroplasia, the unmet medical needs, and the rationale for infigratinib's evaluation [2] - The ongoing Phase 3 PROPEL 3 study of infigratinib is expected to release topline results in Q1 2026 [3] Company Overview - BridgeBio Pharma is a biopharmaceutical company established to develop transformative medicines for genetic diseases, with a pipeline that includes early science to advanced clinical trials [5] - Founded in 2015, the company aims to leverage advances in genetic medicine to expedite patient treatment [5]

Core Viewpoint - Eli Lilly and Company has elected Carolyn R. Bertozzi, Ph.D., as a returning member of its board of directors, effective December 8, 2025, highlighting her significant contributions to targeted medicine development, particularly in oncology [1][2]. Group 1: Board Appointment - Carolyn R. Bertozzi, a Nobel Prize-winning chemist, will serve on the Science and Technology and Ethics and Compliance committees of Lilly's board [1][2]. - David A. Ricks, Lilly's chair and CEO, emphasized the value of Dr. Bertozzi's perspective as the company continues to innovate in oncology and immunology [2]. Group 2: Dr. Bertozzi's Background - Dr. Bertozzi is currently the Baker Family director of Sarafan ChEM-H and a professor at Stanford University, with additional roles in Chemical and Systems Biology and Radiology [2]. - She has received numerous honors and is an elected member of prestigious academies, including the National Academy of Medicine and the National Academy of Sciences [3]. Group 3: Company Overview - Eli Lilly has been a pioneer in medical discoveries for nearly 150 years, focusing on addressing significant health challenges such as diabetes, obesity, Alzheimer's disease, immune system disorders, and difficult-to-treat cancers [4]. - The company is committed to making its medicines accessible and affordable while ensuring diversity in clinical trials [4].

Core Insights - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on genetic diseases, aiming to discover, create, test, and deliver transformative medicines [2] Company Overview - Founded in 2015, BridgeBio has a pipeline that spans from early science to advanced clinical trials, with a commitment to applying advances in genetic medicine [2] - The company is staffed by experienced professionals in drug discovery and development [2] Upcoming Events - Management will participate in fireside chats at the Piper Sandler Healthcare Conference on December 2 at 10:30 am EST and the EvercoreISI HealthCONx Conference on December 3 at 3:00 pm EST [3] - Live webcasts of these presentations will be accessible on the BridgeBio website, with replays available for 90 days post-event [1]

Core Insights - MeiraGTx Holdings plc has announced a strategic collaboration with Eli Lilly in ophthalmology, focusing on the AAV-AIPL1 program for treating Leber congenital amaurosis 4 (LCA4) [1][2] Collaboration Details - MeiraGTx grants Lilly worldwide exclusive rights to the AAV-AIPL1 program, which has shown unprecedented clinical results, restoring vision in 11 legally blind children [2] - Lilly will also gain access to MeiraGTx's gene therapy technologies, including novel intravitreal capsids and AI-generated promoters for retinal applications [3] - The agreement includes an upfront payment of $75 million, with potential milestone payments exceeding $400 million, along with tiered royalties on licensed products [4] Company Background - MeiraGTx is a clinical-stage genetic medicines company with a comprehensive pipeline, including four late-stage clinical programs targeting inherited and common diseases [6] - The company has developed advanced manufacturing capabilities, with five global facilities, including two licensed for GMP viral vector production [6] - MeiraGTx's riboswitch technology allows precise control of gene expression through oral small molecules, applicable to various therapeutic areas [8]

Core Insights - Calidi Biotherapeutics, Inc. is hosting an investor event at the Society of Immunotherapy for Cancer (SITC) Annual Meeting to discuss its RedTail platform and lead candidate CLD-401 [1][2] - The company is conducting IND-enabling studies for CLD-401, targeting non-small cell lung cancer, head and neck cancer, and other high unmet medical need tumor types, with an IND application expected by the end of 2026 [2][4] Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted genetic medicines using its proprietary RedTail platform, which utilizes an engineered enveloped oncolytic virus for systemic delivery to metastatic sites [3][4] - The RedTail platform aims to shield the virus from immune clearance, allowing effective virotherapy to reach tumor sites and deliver potent genetic medicines [3] Event Details - The investor presentation will take place on November 7 from 8:30 AM to 9:30 AM at the Gaylord National Hotel and Convention Center in National Harbor, Maryland, and will be live-streamed [2] - Key speakers at the event include Eric Poma, PhD, CEO of Calidi, and other experts from the Scientific Advisory Board [2][6]

Core Insights - BridgeBio Pharma reported a total revenue of $120.7 million for Q3 2025, driven primarily by $108.1 million in U.S. Attruby net product revenue, alongside $4.3 million from royalty revenue and $8.3 million in license and services revenue [1][3][10] - The company has seen significant commercial progress, with 5,259 unique patient prescriptions written by 1,355 unique prescribers as of October 25, 2025, indicating strong adoption of Attruby since its FDA approval in November 2024 [1][2][4] - BridgeBio plans to file New Drug Applications (NDAs) for BBP-418 and encaleret in the first half of 2026, aiming for full approval of these therapies [1][5][8] Commercial Performance - Attruby's launch has been characterized by strong physician adoption and continued growth across all market segments, reflecting its differentiated clinical profile [4][6] - The company reported a significant increase in total revenues, with a $118 million rise compared to the same period last year, primarily due to the commercial success of Attruby [10][11] Pipeline Developments - Positive interim analysis results from the FORTIFY Phase 3 study of BBP-418 showed a 1.8x increase in glycosylated αDG from baseline at 3 months, with sustained improvements at 12 months [1][8] - The CALIBRATE Phase 3 study of encaleret for ADH1 met its primary endpoint, with 76% of participants achieving target calcium levels at Week 24 [1][8] - The PROPEL 3 study of infigratinib for achondroplasia is fully enrolled, with topline results expected in early 2026 [1][8] Financial Overview - As of September 30, 2025, the company had $645.9 million in cash, cash equivalents, and marketable securities, positioning it well to support the commercialization of Attruby and advance its late-stage pipeline [1][9] - Operating costs for Q3 2025 were $265.9 million, reflecting increased investments in support of Attruby's commercial launch [14][15] Key Metrics - The net loss attributable to common stockholders for Q3 2025 was $182.7 million, compared to $162.0 million for the same period in the prior year, with a net loss per share of $0.95 [22][23] - Total revenues for the nine months ended September 30, 2025, were $347.9 million, up from $216.0 million in the prior year [11][12]

PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host two separate business update calls to share the following: Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) FORTIFY Phase 3 Interim Analysis Topline Results Webinar: Monday, October 27 at 8:00 am ETQ3 2025 Earnings: Wednesday, October 29 at 4:30 pm ET T ...

Core Viewpoint - Regeneron Pharmaceuticals, Inc. is set to report its third quarter 2025 financial and operating results on October 28, 2025, before the U.S. financial markets open [1] Group 1: Financial Reporting - The third quarter 2025 financial results will be announced before the market opens on October 28, 2025 [1] - A conference call and webcast will take place at 8:30 AM Eastern Time on the same day [1] Group 2: Conference Call Information - Participants can access the conference call live via webcast on Regeneron's 'Investors and Media' page [2] - Telephone participants must register in advance to receive a confirmation email with details on how to join the call [2] - A replay and transcript of the conference call will be available on the company's website for at least 30 days [2] Group 3: Company Overview - Regeneron is a leading biotechnology company focused on developing life-transforming medicines for serious diseases [3] - The company is known for its ability to translate scientific research into approved treatments and has a robust pipeline of product candidates [3] - Regeneron's medicines target a wide range of conditions, including eye diseases, cancer, and rare diseases [3] Group 4: Technological Advancements - Regeneron utilizes proprietary technologies like VelociSuite to develop optimized fully human antibodies and bispecific antibodies [4] - The company leverages data from the Regeneron Genetics Center to identify innovative treatment targets [4]